Abstract
OBJECTIVE: The aim of the study was to evaluate the feasibility of functional MR in predicting the clinical response to chemotherapy in patients with colorectal liver metastases (CLM). METHODS: A total of 196 eligible patients were enrolled in the study between August 2016 and January 2023. Functional MR was performed at baseline and after one cycle of chemotherapy. The diffusion kurtosis radiomic texture features were extracted and a signature model was built using the R package. The initial 100 cases were designated as the training set, the following 48 cases were designated as the validation set, and the final 48 cases were designated as the intervention validation set. RESULTS: Good performance for the response prediction (AUC = 0.818 in the training set and 0.755 in the validation set) was demonstrated. The objective response rates (ORRs) in the high-risk subgroup were significantly lower than the low-risk subgroup in the training and validation sets. Worse progression-free survival and overall survival rates were noted in the high-risk population. In the intervention set 22.9% (11/48) of the chemotherapy regimens for patients were changed in response to the model-predicted results and the ORR reached 77.1% (37/48), which was significantly higher than the training and validation sets [47.97% (71/148); P = 0.000]. CONCLUSIONS: A functional MR signature effectively predicted the chemotherapy response and long-term survival. The adjustment of the regimen guided by the model significantly improved the ORR.